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Abstract
Introduction: To achieve epidemic control of HIV by 2030, countries aim to meet 90-90-90 targets to increase knowledge of
HIV-positive status, initiation of antiretroviral therapy (ART) and viral suppression by 2020. We assessed the progress towards
these targets from 2014 to 2016 in South Africa as expanded treatment policies were introduced using population-represen-
tative surveys.
Methods: Data were collected in January to March 2014 and August to November 2016 in Dr. Ruth Segomotsi Mompati Dis-
trict, North West Province. Each multi-stage cluster sample included 46 enumeration areas (EA), a target of 36 dwelling units
(DU) per EA, and a single resident aged 18 to 49 per DU. Data collection included behavioural surveys, rapid HIV antibody
testing and dried blood spot collection. We used weighted general linear regression to evaluate differences in the HIV care
continuum over time.
Results: Overall, 1044 and 971 participants enrolled in 2014 and 2016 respectively with approximately 77% undergoing HIV
testing. Despite increases in reported testing, known status among people living with HIV (PLHIV) remained similar at 68.7%
(95% Confidence Interval (CI) = 60.9–75.6) in 2014 and 72.8% (95% CI = 63.6–80.4) in 2016. Men were consistently less
likely than women to know their status. Among those with known status, PLHIV on ART increased significantly from 80.9%
(95% CI = 71.9–87.4) to 91.5% (95% CI = 84.4–95.5). Viral suppression (<5000 copies/mL using DBS) among those on ART
increased significantly from 55.0% (95% CI = 39.6–70.4) in 2014 to 81.4% (95% CI = 72.0–90.8) in 2016. Among all PLHIV
an estimated 72.0% (95% CI = 63.8–80.1) of women and 45.8% (95% CI = 27.0–64.7) of men achieved viral suppression by
2016.
Conclusions: Over a period during which fixed-dose combination was introduced, ART eligibility expanded, and efforts to
streamline treatment were implemented, major improvements in the second and third 90-90-90 targets were achieved.
Achieving the first 90 target will require targeted and improved testing models for men.
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1 | INTRODUCTION
The global HIV response has gained considerable momentum
in increasing testing and treatment availability in the most
heavily burdened regions. Spurred by findings that viral sup-
pression would benefit not only people living with HIV (PLHIV)
but also prevent transmission to uninfected sexual partners
[1], international agencies and governments have instituted
policies and targets to rapidly expand treatment access.
UNAIDS first introduced testing and treatment targets in
2014 which specify that by 2020, 90% of HIV-positive people
are aware of their status, 90% of those diagnosed receive sus-
tained antiretroviral therapy (ART) and 90% of those on ART
achieve viral suppression [2]. Governments adopted these tar-
gets and have more than doubled the number of people on
ART in recent years. For example, the proportion of PLHIV on
ART in Eastern and Southern Africa increased from 24% in
2010 to 54% in 2015 [3], and reached 60% by 2017 [4].
Home to the most PLHIV, with an estimated HIV preva-
lence of 20.6% among adults 15 to 49, [5] and the largest
national treatment programme, South Africa has progressively
expanded eligibility criteria for ART access [6] and ART
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availability in primary health settings [7]. In 2012, 37.8% of
HIV-positive men and 55.0% of HIV-positive women were
aware of their HIV status [8], 63.1% of men and 68.4% of
women in care were on ART, and 73.7% of those on treat-
ment achieved viral suppression [9]. ART initiation criteria
were extended from CD4 <200 to CD4 <350 in 2013, then
from CD4 <350 to CD4 <500 in January 2015, with universal
test and treatment (ART initiation regardless of CD4 count)
introduced in September 2016 [10]. In addition, the simplicity
of the first-line regimen improved, with South Africa rolling-
out fixed dose combination (FDC) first-line ART (comprised of
Tenofovir/Emtricitabine/Efavirenz) in April 2013 [11]. Finally,
additional efforts to streamline treatment with strategies such
as providing fast track ART pick-up with longer medication
supplies for stable patients were introduced in 2016 [12].
Introduction of FDC, expanded ART eligibility, and new mea-
sures to streamline treatment and improve adherence are
likely to make a large impact on care engagement and adher-
ence, moving South Africa closer to meeting the 90-90-90 tar-
gets following these policy changes. In fact, the summary
findings of the National HIV Prevalence, Incidence, Behaviour
and Communication Survey 2017 note recent improvements
in 90-90-90 targets. Although targets vary regionally, survey
findings estimated that nationally, 78.0% and 88.9% of HIV-
positive males and females respectively were aware of their
status; 67.4% and 72.2% of males and females aware of their
status were on ART; and 82.1% and 89.9% and of males and
females on ART were virally suppressed [5].
We implemented two sequential population-representative
surveys in 2014 and 2016 in two municipalities in North
West Province (NW). The surveys were conducted in conjunc-
tion with an HIV prevention programme, providing an oppor-
tunity to both evaluate the impact of an HIV prevention
programme focusing on increasing HIV testing uptake through
community-based testing campaigns and home-based testing
services, and to assess trends in the HIV care continuum in
an understudied but high prevalence area. While we had
hypothesized that HIV testing and care engagement would
increase in the municipality receiving the combination preven-
tion programme compared to the municipality not receiving
these services, we found that changes in the 90-90-90 indica-
tors between the two communities were equivalent. However,
changes over time in the 90-90-90 indicators in both commu-
nities reflect trends with important implications in evaluating
the impact of national policies because the surveys were
implemented at different stages of national ART access expan-
sion. As a result, we describe changes in the 90-90-90 targets
through comparison of population-based data from the two
municipalities before (early 2014) and after (late 2016)
expanded treatment policies were introduced.
2 | METHODS
2.1 | Study setting and sampling
Data collection was conducted in Lekwa-Teemane and Greater
Taung municipalities within Dr. Ruth Segomotsi Mompati
(RSM) District. RSM has both rural and peri-urban areas, with
approximately 230,000 total inhabitants, including approxi-
mately 93,000 adults aged 18 to 49. The estimated 503,766
PLHIV in North West, where 6.7% of the country’s population
resides, accounts for approximately 7.1% of the South African
epidemic [13]. Adult HIV prevalence in NW is currently esti-
mated at 22.7% [5]. When the research was underway, the
North West had the fourth highest provincial prevalence but
the lowest treatment engagement numbers in the country,
with the Provincial AIDS Council estimating in 2015 that only
half (51%) of PLHIV aware of their status were on ART [14].
Study locations were identified in partnership with the Provin-
cial Department of Health and represent areas with few HIV
prevention and care initiatives. Surveys were conducted
between January and March 2014, and again between August
and November, 2016. In the interim (mid 2014–mid 2016)
prevention activities were conducted in Lekwa-Teemane, but
not in Greater Taung. Activities included events offering com-
munity-based and home-based HIV testing, referrals to care
and treatment, and screening and referrals for sexually trans-
mitted infections and tuberculosis.
Initial sample size calculations reflected targets needed for
a comparison of communities over time, with power to detect
50% increase in recent HIV testing. We employed a multistage
cluster sampling approach in collaboration with Statistics
South Africa to access a representative sample of municipality
households. Both surveys included 23 enumeration areas
(EAs) from each municipality (n = 46 EAs total) selected pro-
portionate to size based on 2011 census data. Prior to the
2014 survey, all dwelling units (DU) in selected EAs were fully
enumerated, including a detailed listing of residents. The listing
was used to randomly select up to 36 inhabited dwelling units
(DU) or households from each EA for inclusion (1561 DUs in
total). One adult (18 to 49 years) was randomly selected per
DU for participation [15]. In 2016, sampled EAs were enumer-
ated using aerial maps including all structures within the EA
boundary; research teams then drove through the EAs to note
structures that were no longer inhabited and/or new struc-
tures to add to the map. Within each EA, 46 DUs were ran-
domly selected; a higher number of households were selected
in 2016 to account for the probability that not all DUs would
have an eligible adult. Eligibility was assessed during fieldwork:
at each selected DU research staff listed all eligible residents
18 to 49 years and used a random number generator to
select an individual from the household list for inclusion.
Across surveys the EAs ranged in size from 14 to 355 dwell-
ings, resulting in probability of DU selection ranging from 1.0
to 0.13. Results and detailed methods from the first survey
have been published [15].
2.2 | Data collection
For each survey, fieldworkers confirmed participant eligibility
criteria (18 to 49 years, able to provide informed consent,
and household residence defined as sleeping in the DU four
or more nights per week); obtained written informed consent;
and conducted a computer-assisted personal interviewing
(CAPI) survey at the participant’s home in the preferred lan-
guage (English or Setswana). The surveys elicited demographic
characteristics, HIV testing and treatment history, health ser-
vices utilization, sexual and other risk behaviours, and commu-
nity characteristics. Participants were compensated with a
mobile phone airtime voucher.
Following the survey, point-of-care HIV rapid antibody test-
ing was performed by trained community health workers
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(CHWs) using serial HIV-1/2 antibody rapid testing using the
Alere Determine HIV-1/2 (Alere Medical Co., Ltd, Chiba,
Japan) and, if reactive, the First Response HIV 1-2 (Premier
Medical Corporation Ltd, Daman, India) [15]. Participants test-
ing positive or with discrepant results were asked to undergo
lancet finger-prick to create ten 50 lL dried blood spots
(DBS) using one Munktell filter card (Ahlstrom Munktell, Hel-
sinki, Finland) and one Whatman Protein Saver #903 card,
and then referred to the nearest public health care facility.
Participants who declined rapid testing were asked to provide
blood for DBS for laboratory HIV diagnosis (serology: ELISA
confirmed with Western blot) and offered a study number to
call for the results. DBS cards were dried, stored with desic-
cant at ambient temperature, transported to the study labora-
tory within six days of collection, and stored at 70°C prior
to viral load, ART exposure testing and HIV serology (when
point-of-care antibody testing was declined or discrepant).
All procedures were approved by the Committee for
Human Research at the University of California, San Francisco
(UCSF), the Human Subjects Division at University of Wash-
ington; the Human Sciences Research Council Research Ethics
Committee in South Africa; the Policy, Planning, Research,
Monitoring and Evaluation Committee for the North West
Provincial Department of Health; and the CDC’s Center for
Global Health, Human Research Protection.
2.3 | Laboratory procedures
Viral load testing was performed on Munktell DBS using the
COBAS AmpliPrep for sample preparation and COBAS Taq-
Man HIV-1 2.0 test (Roche Applied Science, Pleasanton CA,
USA; lower limit of quantification 400 copies/mL for DBS)
[16]. We utilize a conservative viral suppression cut off of
<5000 copies/mL, which is a higher threshold than recom-
mended for plasma due to the combined quantification of
both proviral DNA (present in settings of viral RNA suppres-
sion) and cellular RNA in DBS samples [17].
ART exposure was determined using the Whatman Protein
Saver #903 cards by a validated qualitative liquid chromatog-
raphy MS/MS method to determine the presence of antiretro-
viral analytes against cutoff samples for the following three
drugs: efavirenz, lopinavir, nevirapine, found in first and sec-
ond-line regimens.
2.4 | Measures
Participant sociodemographic characteristics (sex, age, citizen-
ship/resident status, past year employment, marital status,
educational attainment and past month household food inse-
curity) and prior HIV testing behaviour were self-reported.
HIV status was determined through rapid or laboratory-based
HIV-1/2 antibody testing, as described above.
Elements of the HIV care continuum were defined as follows:
Prior knowledge of status includes HIV-positive participants
reporting a prior positive test or ART analyte positive results.
Linked to care was defined as reporting ever seeing a health
professional for HIV care with ideal linkage defined as seeing a
care provider and completing CD4 testing within three months
of diagnosis. Retained in care among ART-eligible was defined as
currently on ART and seeing a care provider every three
months in the past year and among ART-ineligible was defined
as seeing a care provider and undergoing CD4 testing the past
year. In 2016, South Africa introduced guidance designed to
encourage clinically stable patients to undergo clinical assess-
ments only once per year and to retrieve ART for longer inter-
vals; however, because we cannot know which patients were
included in that programming, we utilize the same definition at
each time point [12]. On ART was defined as analyte-positive
for those with analyte results or by self-reported current ART
use. Analyte- positive included those DBS positive for efavirenz,
lopinavir or nevirapine. Viral suppression was defined as DBS
viral load <5000 copies/mL, although we also assess thresholds
at <1000 and <3000) [17]. For any participants with conflicting
information (e.g. reported unknown status but tested positive
for ART analytes), we prioritized the objective marker over
self-report, as individuals may either not have understood the
questions or chosen not to disclose for their own reasons [18].
2.5 | Analysis
All analyses accommodated the multi-stage survey design,
including clustering and weighting [19]. Weights were cre-
ated using the inverse probability of selection at each stage
(EA, DU and person) and adjusted for non-response to
reflect municipality age and sex distributions [20]. We calcu-
lated proportions and 95% confidence intervals (CIs) to
describe overall and sex-specific demographic characteristics,
HIV testing, prevalence and care engagement. One study
participant self-reported as transgender in 2016; because
sampling was based on biological sex, this individual was
included in subsequent analyses in their biological sex group
(male). We estimated chi-square statistics using the second-
order Rao and Scott correction for bivariate analyses [21].
Given the aim to evaluate a comprehensive prevention pro-
gramme, we first estimated difference-in-differences models
to assess changes over time within and by municipalities
using generalized linear mixed effects logistic regression
models, including a random intercept for enumeration area,
our stratification variable and the Huber variance estimator
for cluster-robust standard error estimation [22]. We found
that reported past-year HIV testing was statistically higher in
Lekwa-Teemane as compared to Greater Taung; however,
care continuum outcomes, including known HIV status, did
not change differentially by municipality. We therefore pre-
sent combined municipal data in the current analysis compar-
ing 2014 to 2016 data. We used generalized linear
regression modelling (GLM) with log binomial models to eval-
uate differences in the HIV care continuum between 2014
and 2016. We first imputed missing data on HIV status and
DBS outcomes (analyte and viral load) using multiple imputa-
tion by chained equations procedures, employing 50 datasets
from models incorporating socio-demographic, clinical and
behavioural predictors. To account for our study design,
imputation models included enumeration area and survey
weights, and main analyses employed survey procedures
[23]. Differences where p < 0.05 were considered statisti-
cally significant. Analyses were performed using Stata version
14 (StataCorp, College Station, TX, USA).
We conducted sensitivity analyses to ensure that any differ-
ences in sample composition between the two surveys did not
influence findings. Using inverse probability weights, we
reweighted the 2014 data to make it comparable to the 2016
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sample in terms of the following participant characteristics:
age group, educational attainment, marital status, South Afri-
can citizenship, past year income and past month food insecu-
rity. Final stabilized weights also accounted for the sex and
age-specific probability of being in one’s observed survey year,
whether 2014 or 2016. This approach is mathematically
equivalent to direct standardization (i.e. by age) to encompass
multiple differences in underlying demographics [24,25].
2.6 | Role of the funding source
This project has been supported by the U.S. President’s Emer-
gency Plan for AIDS Relief (PEPFAR) through the U.S. Centers
for Disease Control and Prevention (CDC) under the terms of
Cooperative Agreement 5U2GGH000324. Additional support
was received through the UCSF-Gladstone Institute of Virol-
ogy & Immunology Center for AIDS Research (CFAR), an NIH-
funded programme (P30 AI027763). The CDC reviewed the
protocol. Funders had no involvement in the data collection,
interpretation, writing or the decision to submit a manuscript.
3 | RESULTS
In 2014, 43 of the 46 selected EAs were successfully enumer-
ated; fieldworkers were not granted access to three farm
areas. Of the 1527 enumerated DUs, 98.5% were approached;
contact was made at 91.7%, yielding 1146 eligible individuals.
A total of 1048 (91.0% of eligible participants) consented to
participate; four were later determined ineligible (due to field-
worker error enrolling a non-selected DU member), resulting
in a total sample of 1044. Median cluster size was 25 (IQR: 22
to 28). In 2016, we approached 1925 DUs (95.7% of those
targeted) in 46 selected EAs and were able to assess 1571
(81.6% of those approached) for study eligibility; 1060 (67.5%)
dwellings had at least one eligible household member. A total
of 980 participants (92.5%) enrolled; six were later determined
ineligible (enrolment of non-selected DU or DU member), data
were lost for two surveys due to errors saving and uploading
the survey files, and one survey was not matched to a house-
hold, resulting in an analytic sample of 971 participants. Med-
ian cluster size in 2016 was 21.5 (IQR: 17 to 27). Most
common reasons for declining participation in both surveys
were reported disinterest, lack of time and not feeling well.
Across the surveys, 77.1% consented to HIV testing through
rapid test or DBS (n = 1555).
Just over half of study participants were female (53.0%)
and 49% were aged 18 to 29 years. (Table 1). Nearly all par-
ticipants were South African citizens or permanent residents.
The only characteristic that differed significantly between
2014 and 2016 samples was past year employment, at 54%
and 30% in 2014 and 2016 respectively. Most participants
were single or non-cohabitating (70.3% and 72.5% in 2014
and 2016 respectively), and one quarter reported past month
food insecurity (25.7% and 23.0% respectively).
3.1 | HIV prevalence and testing behaviours
HIV prevalence did not vary significantly across time at 22.8%
(95% CI 18.2–27.5) in 2014 and 21.2% (CI 16.7–25.6) in 2016
(Table 2). HIV prevalence was consistently lower for men
compared to women at 18.7% (CI 12.7–24.7) versus 26.5% (CI
21.3–30.9; p = 0.029) in 2014 and 15.0% (CI 9.5–20.5) versus
26.6% (CI 20.4–32.8; p = 0.006) respectively. At both time
points, approximately four-fifths of study participants reported
having ever tested for HIV (79.7% and 81.3% respectively;
Table 2), with higher proportions of females reporting ever
testing. Data on past-year HIV testing suggested an increasing
but not significant trend over time; overall, 51.0% (CI 46.4–
55.6) of 2014 participants and 55.0% (CI 50.3–59.5) of 2016
participants reported past-year HIV testing; men consistently
reported less testing than women.
3.2 | The HIV care continuum
We assessed changes to the HIV care continuum over time
among the HIV-positive population to assess improvements in
engagement in care (Table 2). Both the proportion of HIV-
positive participants with known status and the proportion
linked to care were similar over time, although reported link-
age within three months of diagnosis fell among both men
and women (Table 2). Retention in care increased from 49.2%
in 2014 to 58.4% in 2016, but was not statistically significant.
Similarly, the proportion either reporting being on ART or with
evidence of ART analytes increased from 56.2% to 67.2%; this
difference was marginally statistically significant (p = 0.056).
Increases observed over time in the proportion of PLHIV who
tested analyte positive, indicating ART uptake and use, were
also marginally significant at 51.0% (CI 43.5–58.5) in 2014
compared to 62.6% (CI 52.9–72.2) in 2016 (p = 0.058). Large
improvements in viral suppression across time were observed.
In 2014, 37.3% (CI 28.4–46.2) of all PLHIV were virally
suppressed at <5000 copies/mL compared to 63.3% (CI 54.6–
72.0) in 2016 (p < 0.001); with similar improvements in sup-
pression across thresholds and large improvements for both
sexes. The HIV care continuum is also presented by sex in Fig-
ures S1 and S2.
3.3 | 90-90-90 targets
Prior knowledge of HIV status among all HIV positive individ-
uals (the first “90”) was consistent over time at 68.7% (CI
60.9–75.6) in 2014 compared to 72.8% (CI 63.6–80.4) in
2016 (Table 3; Figure 1). Prior knowledge of status was con-
sistently lower among men both in 2014 and 2016. The pro-
portion of PLHIV who knew their status that had evidence of
currently being on ART (the second “90”) increased signifi-
cantly from 80.9% (CI 71.9–87.4) in 2014 to 91.5% (CI 84.4–
95.5) in 2016. Increases were marginally statistically signifi-
cant for women (p = 0.060) and improvements were not sig-
nificant for men (p = 0.287). Among those individuals on ART,
viral suppression (the third “90”) increased significantly over
time; 55.0% (CI 39.6–70.4) of the sample had viral load
<5000 copies/mL in 2014 compared to 81.4% (CI 72.0–90.8)
in 2016. There was a particularly large increase observed for
males (33.7% to 81.6%), bringing viral suppression to equiva-
lent levels among men and women by 2016. Despite the
improvements in men engaging in care, overall differences in
the achievement of 90-90-90 targets by sex are largely due
to the stark disparities in testing and knowledge of HIV status,
with HIV-positive men less likely to have been diagnosed. This
is evidenced in the composite target of having 73% of all
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PLHIV virally suppressed. Using our imputation model (instead
of multiplying out the three 90s), our findings indicate that
63.3% of PLHIV in the research area overall were virally sup-
pressed; however, 72.0% of women achieved viral suppression
– very close to the 73% target and far outperforming men at
45.8% (represented in Figure 1).
Sensitivity analyses standardizing the 2014 to the 2016 pop-
ulation did not substantively change our results, with the excep-
tion of recent HIV testing: the difference in the proportion
reporting past-year HIV testing in sensitivity analysis was
54.8% versus 61.4% (p = 0.025) in 2014 versus 2016 as com-
pared to 51.0% versus 55.0% (p = 0.093) in the main analysis.
However, findings regarding the care cascade and 90-90-90
targets remained consistent in sensitivity analyses, including the
absence of differences in known status over time, implying that
while there was potentially more testing underway in 2016 as
compared to 2014, this did not translate into more diagnoses.
4 | DISCUSSION
Using data from recent consecutive population-representative
surveys in two municipalities in North West Province, South
Africa, we found strong evidence that HIV care engagement
has improved in recent years. We found notable advances in
both the second and third 90-90-90 targets. The proportion
of PLHIV with known status who are on treatment reached
91% and the proportion of virally suppressed on treatment is
estimated at 81%. Although our results suggest that preven-
tion activities led to a higher proportion of individuals
reporting HIV testing, these activities did not result in
improvements in the first 90 target. Increased testing alone
did not improve the proportion of PLHIV who knew their sta-
tus, which remained similar over time at 69% in 2014 and
73% in 2016. Our findings suggest that shifts in the national
programme are the drivers of change in these communities, as
opposed to introduction of local activities designed to enhance
testing and engagement in care. This finding is consistent with
recent community trials, such as the ANRS Treatment as
Prevention (TasP) trial in South Africa, which similarly found
no difference in ART coverage in communities receiving a test
and treat intervention as compared to a control condition, but
demonstrated improvements overall between 2012 and 2016
during treatment expansion [26].
Our estimates of known status, the first 90, remained consistent
at around 55% of men and 80% of women in 2014 and 2016, with
Table 1. Socio-demographic characteristics of study participants in 2014 and 2016, North West Province, South Africa
2014 Survey 2016 Survey
p value
n = 1044 n = 971
n weighted % 95% CI n weighted % 95% CI
Sex
Male 401 47.0 41.7–52.2 393 46.8 42.0–51.7 1.000
Female 643 53.0 47.8–58.3 577 53.0 48.1–57.9
Trans 0 - - 1 0.1 0.0–1.0
Age group
18 to 29 years 453 49.0 45.2–52.8 514 49.0 44.5–53.4 1.000
30 to 39 years 344 28.0 24.9–31.2 289 28.1 24.1–32.4
40 to 49 years 247 23.0 20.0–26.0 168 23.0 18.3–28.4
South African citizen or permanent residenta 1035 99.4 98.9–99.9 966 99.6 98.4–99.9 0.682
Municipality
Greater Taung 557 73.8 63.6–82.0 527 73.8 71.9–83.1 1.000
Lekwa-Teemane 487 26.2 18.0–36.4 444 26.2 16.9–38.1
Employed past 12 months 629 53.9 48.8–59.0 289 30.0 25.5–35.0 <0.001
Marital status
Married/living with partner 321 25.8 21.2–30.4 243 23.5 18.7–27.7 0.792
Single/in relationship 675 70.3 65.7–75.0 688 72.5 68.1–76.5
Single (separated/divorced) 27 2.1 1.1–3.1 24 2.4 1.5–2.7
Single (widowed) 21 1.7 0.9–2.5 16 1.7 0.9–3.1
Educational attainment
Primary or less 241 21.0 16.8–25.2 178 18.7 14.7–23.6 0.288
Some secondary 431 43.7 38.5–48.9 417 41.6 36.9–46.6
Completed secondary 299 27.6 23.2–32.1 322 34.2 29.8–38.9
College/university or technikon 73 7.7 3.4–12.1 54 5.4 3.2–9.0
Any food insecurity past month 258 25.7 20.3–31.0 205 23.0 17.3–29.9 0.520
Weights account for sampling, non-response and age/sex of target population, including size of municipality.
aMissing responses for three participants.
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only small, non-significant increases. Our estimates are slightly
higher than those from a comparable survey in KwaZulu-Natal,
where 52% of HIV-positive men and 65% of women knew their
status in 2014 to 2015 [27], lower than another, similar study not-
ing 68% of status knowledge among men, [28] and much lower
than the 91.5% (overall) reported in the ANRS TasP trial [26]. Our
estimates are slightly lower than 2015 to 2016 national estimates
of 74% with known status [29], and much lower than modelled
estimates from mid-2016 of 84% to 89% across provinces [30].
They also diverge considerably from the 2017 National HIV Sur-
vey Summary, which estimated that 78.0% and 88.9% of HIV-posi-
tive males and females respectively are aware of their status [5].
The first “90” is the most difficult proportion to estimate as high
quality data on the number of people who are living with HIV (the
total population who should be included in the denominator), are
not available [31]. Also difficult to come by are precise estimates
of how many diagnoses have been made (those who should also
be in the numerator). Other discrepancies and the wide range of
estimates of the first 90 might be due to large regional differences
in testing uptake; although national and regional data in this case
are similar. Nonetheless, our findings contribute to growing evi-
dence that diagnosis remains a major barrier to achieving 90-90-
90 [32] and to the increasing consensus that given the large dis-
parity in knowledge of status among men, who test less frequently
and who have poorer HIV outcomes over the lifecourse as com-
pared to women [33]; new programming must creatively target
men [9,34,35].
Our findings regarding the second 90 target, “on ART,” that
88.6% of men and 92.4% of women with known status are on
treatment, are higher than similar surveys [27,28] and national
estimates [5]. National HIV Survey Summary data estimate
only 67.4% and 72.2% of males and females, respectively are
on ART. However, this discrepancy is likely due to differences
in calculating the denominator; if more people are believed to
know their status, then the number on treatment will reflect a
smaller proportion. Conversely, if fewer people are believed to
know their status, the estimate of the proportion on treat-
ment will be higher. Estimates of the third 90 in South Africa
are reliably over 80% [5,26,27], which is consistent with our
data. Our findings on the overall proportion of PLHIV who are
virally suppressed, with 46% of men and 72% of woman living
with HIV reaching viral suppression, are higher than the
national survey findings of 43% and 58% of male and female
PLHIV achieving suppression [5], and higher than the mod-
elled provincial data for North West Province [36]. These dif-
ferences may be due to our use of an unconditional
imputation model, as opposed to simple multiplication of the
90-90-90 estimates. Our model allows for HIV-positive partici-
pants who may not know their status or be on treatment to
have low viral loads suggestive of suppression, as this was
observed in our data and has been found elsewhere [37].
Additionally, our higher estimate of total viral suppression
could be due to utilizing the higher viral suppression threshold
of < 5000, based on the sample medium.
These data were collected during rapid treatment scale up
and multiple treatment guideline revisions. The South African
National Department of Health (NDoH) introduced the first line
FDC, single pill (TDF/FTC/EFV), in 2013. As the new FDC was
implemented in stages, it is likely that some patients in rural
areas were still being transitioned to FDC in early 2014, at the
time of the first survey, whereas by 2016 all clients would haveT
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been on a FDC regimen. Single-pill regimens have been found to
improve medication adherence [38], increase patient satisfaction
[39], and can improve clinic attendance [40]. Medication monitor-
ing and storage is easier when patients and providers need to
keep track of only one pill. Furthermore, the NDoH extended
ART qualifying criteria twice in the interim of the two surveys,
with implementation of treatment access for those with CD4
<500 in 2015, after the first survey, and universal access to care
implemented approximately as the second survey began. While it
is unlikely that universal access was implemented uniformly and
immediately with the announcement, the ART expansion in 2015
likely had a large impact on increased the number of people on
treatment and suppressed between the surveys. During this
time, the government also introduced new adherence guidelines
with efforts to streamline treatment, providing means to more
rapid and longer ART prescribing for stable patients, along with
introduction of strategies such as community adherence clubs in
2016. Finally, the health department also published more exten-
sive guidance around tracing patients defaulting from care,
including a push for PEPFAR partners to oversee implementation
of partner tracing, which might have contributed to re-engage-
ment of patients.
In the full HIV-positive population, we noted an approxi-
mately 9% point increase in reported retention in care
(p = 0.139), a 12% point increase in the presence of ART
analytes (p = 0.058), and 26% point increase in viral suppres-
sion (p < 0.001). We believe that the structural, policy-level
changes are largely responsible for the improvement in ART
adherence and viral suppression. Others have attributed simi-
lar findings on improvements in initiation rates and therapeu-
tic response to changes in guidelines [32]. It is also possible
that improvements in the later “90”s may be due to changes
in social context of HIV treatment, including reduced
stigma or increased comfort with disclosure and support
seeking.
This study compared two sequential, population-representative
samples of the general population aged 18 to 49 years in North
West Province, South Africa during a period of rapid policy tran-
sition. Our findings are representative of an area of comprising
230,000 people and provide insight into the impacts of policy
changes in South Africa’s HIV response in a district far from the
major metropolitan areas. Our findings are subject to some
biases. While fewer than 10% of eligible participants declined
survey participation, 23% declined HIV testing in our survey.
Our participation rates are still higher than the national survey,
in which only 67.7% and 58.4% of men and women respectively
agreed to HIV testing [5]. We accounted for non-response and
multiply imputed missing data; however, these estimates are sub-
ject to bias if refusals were differential by HIV-status [41]. Self-
reported knowledge of status, linkage to care and retention in
care is subject to misreporting. Guidance around the frequency
of visits changed for stable patients between the surveys, which
likely explains why our estimate of retention is lower than our
estimate of those positive for ART analytes in 2016. Viral sup-
pression is estimated from DBS; we used a high (>5000 copies/
mL) threshold for defining viral suppression, as cellular proviral
HIV DNA and virion RNA both contribute to copy number when
using DBS instead of plasma from whole blood [17]. As a result,
viral suppression estimates might be inflated. However, we see
similar improvements in viral suppression using all thresholds.
Furthermore, while there were some differences between 2014
and 2016 samples, sensitivity analysis aimed at improving sample
comparability yielded similar results.
5 | CONCLUSIONS
Over the span of two and a half years during which the first
line FDC was introduced, CD4 thresholds were steadily
removed for ART eligibility, and guidance was published on
20
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Figure 1. Progress towards 90-90-90 Targets: conditional and unconditional (Composite) knowledge of HIV status, ART initiation and viral
suppression in 2014 and 2016, North West Province, South Africa.
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facilitating treatment and tracking defaulting patients, we
found that the second 90-90-90 target was reached and the
third is within reach in a rural area of North West Province,
South Africa. We conclude that South Africa’s policies have
improved and facilitated access to treatment. No significant
improvements were evident in the first 90 target, despite
testing campaigns in the area and increases in reported HIV
testing. Our findings indicate that by late 2016, women in the
research area had almost achieved the 73% suppression tar-
get. Our data also indicate that woman far outperform men in
meeting this target, a finding common to recent large-scale
trials [42]. It is possible that South Africa can meet the ambi-
tious targets, but only if detection of infection among men is
improved. This will require targeted and differentiated testing
models to encourage uptake of HIV testing by men and others
less inclined to attend a clinic. Accordingly, South Africa’s new
National Strategic Plan [43] calls for expanded testing services
delivered outside health facilities, including self-screening [44],
with efforts to target men, adolescents and other populations
not accessing testing services to close testing gaps. By
expanding testing models beyond current clinic-based
approaches and pairing testing with facilitated linkage strate-
gies, South Africa may be able in a position to meet its targets
and grow closer to ending the threat of the HIV epidemic.
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